3209 |
Long-Term Durability Issue of TAVR; Uncertainty or Would Be OK |
Duk-Woo Park |
Apr. 25. 17 |
3208 |
TAVI: A 15 Years Clinical Experience from FIM |
Helene Eltchaninoff |
Apr. 25. 17 |
3207 |
Bicuspid and Valve-in-Valve; How Different? |
Jung-Min Ahn |
Apr. 25. 17 |
3206 |
Specific Valve for Specific Patient; How to Do Tailored Selection? |
Darren L. Walters |
Apr. 25. 17 |
3205 |
Ongoing TAVR Trials and Updating TAVR Guidelines |
Eberhard Grube |
Apr. 25. 17 |
3204 |
Atrial Fibrillation & Antithrombotic Regimens: Finding the \"Sweet-Spot\" from RCTs |
Freek W.A. Verheugt |
Apr. 25. 17 |
3203 |
Bioresorbable Vascular Scaffolds and DAPT Duration: The Longer the Better? |
David Joel Cohen |
Apr. 25. 17 |
3202 |
Ad Hoc Versus Staged PCI for Multivessel Disease: Safety First, Choose Wisely! |
Neal S. Kleiman |
Apr. 25. 17 |
3201 |
[Debate II: How to Find Ischemia?] iFR Can Be a Gold Standard. |
Justin E. Davies |
Apr. 25. 17 |
3200 |
[Debate II: How to Find Ischemia?] FFR Is a Gold Standard. |
Nils Johnson |
Apr. 25. 17 |